Michael Ackermann's Insider Trades & SAST Disclosures
Michael Ackermann's most recent trade in Tarsus Pharmaceuticals Inc was a trade of 12,000 Restricted Stock Units done . Disclosure was reported to the exchange on June 16, 2022.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael Ackermann.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 12,000 | 12,000 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 7,000 | 7,000 | - | - | Stock Option (right to buy) | |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2022 | 4,257 | 0 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2022 | 4,257 | 1,208,273 | - | - | Common Stock | |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Purchase of securities on an exchange or from another person at price $ 13.50 per share. | 05 May 2022 | 100,000 | 100,000 | - | 13.5 | 1,350,000 | Common Stock |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Sale of securities on an exchange or to another person at price $ 27.76 per share. | 01 Nov 2021 | 4,964 | 1,210,718 | - | 27.8 | 137,801 | Common Stock |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Sale of securities on an exchange or to another person at price $ 28.18 per share. | 01 Nov 2021 | 869 | 1,209,849 | - | 28.2 | 24,488 | Common Stock |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Sale of securities on an exchange or to another person at price $ 26.45 per share. | 12 Oct 2021 | 4,517 | 1,215,682 | - | 26.5 | 119,475 | Common Stock |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Sale of securities on an exchange or to another person at price $ 25.56 per share. | 12 Oct 2021 | 1,116 | 1,220,199 | - | 25.6 | 28,525 | Common Stock |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Sale of securities on an exchange or to another person at price $ 25.03 per share. | 08 Oct 2021 | 200 | 1,221,315 | - | 25.0 | 5,006 | Common Stock |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Sale of securities on an exchange or to another person at price $ 25.24 per share. | 01 Sep 2021 | 5,833 | 1,221,515 | - | 25.2 | 147,237 | Common Stock |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Sale of securities on an exchange or to another person at price $ 25.15 per share. | 11 Aug 2021 | 621 | 1,227,348 | - | 25.2 | 15,619 | Common Stock |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 06 Aug 2021 | 3,129 | 1,228,669 | - | 25 | 78,225 | Common Stock |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 06 Aug 2021 | 700 | 1,227,969 | - | 25 | 17,500 | Common Stock |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 05 Aug 2021 | 1,183 | 1,231,998 | - | 25 | 29,575 | Common Stock |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 05 Aug 2021 | 100 | 1,231,898 | - | 25.0 | 2,501 | Common Stock |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 05 Aug 2021 | 100 | 1,231,798 | - | 25.0 | 2,501 | Common Stock |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 4,257 | 1,233,181 | - | 0 | Common Stock | |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 4,257 | 4,257 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director, Ten Percent Owner | 20 Oct 2020 | 53,939 | 1,219,678 | - | - | Common Stock | ||
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director, Ten Percent Owner | 20 Oct 2020 | 53,939 | 0 | - | - | Series A Preferred Stock | ||
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director, Ten Percent Owner | 20 Oct 2020 | 9,246 | 0 | - | - | Series B Preferred Stock | ||
| Tarsus Pharmaceuticals Inc | Michael Ackermann | Director, Ten Percent Owner | 20 Oct 2020 | 9,246 | 1,228,924 | - | - | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges